Cargando…

Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson’s disease using in vivo (18)F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging

(18)F-9-Fluoropropyl-(+)-dihydrotetrabenazine [(18)F-FP-(+)-DTBZ] positron emission tomography (PET) has been shown to detect dopaminergic neuron loss associated with Parkinson’s disease (PD) in human and neurotoxin-induced animal models. A polyphenol compound, magnolol, was recently proposed as hav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weng, Chi-Chang, Chen, Zi-An, Chao, Ko-Ting, Ee, Ting-Wei, Lin, Kun-Ju, Chan, Ming-Huan, Hsiao, Ing-Tsung, Yen, Tzu-Chen, Kung, Mei-Ping, Hsu, Ching-Han, Wey, Shiaw-Pyng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336287/ https://www.ncbi.nlm.nih.gov/pubmed/28257461 http://dx.doi.org/10.1371/journal.pone.0173503

Ejemplares similares

PET Imaging a MPTP-Induced Mouse Model of Parkinson’s Disease Using the Fluoropropyl-Dihydrotetrabenazine Analog [(18)F]-DTBZ (AV-133)
por: Toomey, James S., et al.
Publicado: (2012)

A Multi-Atlas-Based [18F]9-Fluoropropyl-(+)-Dihydrotetrabenazine Positron Emission Tomography Image Segmentation Method for Parkinson’s Disease Quantification
por: Pan, Yiwei, et al.
Publicado: (2022)

Brain Imaging of Vesicular Monoamine Transporter Type 2 in Healthy Aging Subjects by (18)F-FP-(+)-DTBZ PET
por: Lin, Kun-Ju, et al.
Publicado: (2013)

Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine
por: Skor, Heather, et al.
Publicado: (2017)

Synthesis and analysis of 4-(3-fluoropropyl)-glutamic acid stereoisomers to determine the stereochemical purity of (4S)-4-(3-[(18)F]fluoropropyl)-L-glutamic acid ([(18)F]FSPG) for clinical use
por: Shih, Kai-Ting, et al.
Publicado: (2020)

Regional Amyloid Deposition in Amnestic Mild Cognitive Impairment and Alzheimer's Disease Evaluated by [(18)F]AV-45 Positron Emission Tomography in Chinese Population
por: Huang, Kuo-Lun, et al.
Publicado: (2013)

[(18)F](2S,4S)-4-(3-Fluoropropyl)glutamine as a Tumor Imaging Agent
por: Wu, Zehui, et al.
Publicado: (2014)

Visualization of ischemic stroke-related changes on (18)F-THK-5351 positron emission tomography
por: Huang, Kuo-Lun, et al.
Publicado: (2018)

Radiosynthesis and Analysis of (S)-4-(3-[(18)F]Fluoropropyl)-L-Glutamic Acid
por: Brown, Gavin, et al.
Publicado: (2022)

Magnolol Protects against MPTP/MPP(+)-Induced Toxicity via Inhibition of Oxidative Stress in In Vivo and In Vitro Models of Parkinson's Disease
por: Muroyama, Akiko, et al.
Publicado: (2012)

Investigation of reactive astrogliosis effect on post-stroke cognitive impairment
por: Huang, Kuo-Lun, et al.
Publicado: (2020)

(+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia
por: Wang, Wenyan, et al.
Publicado: (2021)

Insights on the Multifunctional Activities of Magnolol
por: Zhang, Jianhong, et al.
Publicado: (2019)

Characteristic patterns of inter- and intra-hemispheric metabolic connectivity in patients with stable and progressive mild cognitive impairment and Alzheimer’s disease
por: Huang, Sheng-Yao, et al.
Publicado: (2018)

Antinociceptive actions of honokiol and magnolol on glutamatergic and inflammatory pain
por: Lin, Yi-Ruu, et al.
Publicado: (2009)

(18)F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty
por: Hsu, Jung-Lung, et al.
Publicado: (2020)

Pilot Preclinical and Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-Glutamate (18F-FSPG) for PET/CT Imaging of Intracranial Malignancies
por: Mittra, Erik S., et al.
Publicado: (2016)

Author Correction: (18)F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty
por: Hsu, Jung-Lung, et al.
Publicado: (2021)

Tau PET With (18)F-THK-5351 Taiwan Patients With Familial Alzheimer's Disease With the APP p.D678H Mutation
por: Huang, Chin-Chang, et al.
Publicado: (2019)

Synthesis and Biological Evaluation of O-[3-(18)F-fluoropropyl]-α-methyl Tyrosine in Mesothelioma-Bearing Rodents
por: Shih, I-Hong, et al.
Publicado: (2013)

Investigation of a Potential Scintigraphic Tracer for Imaging Apoptosis: Radioiodinated Annexin V-Kunitz Protease Inhibitor Fusion Protein
por: Liao, Mei-Hsiu, et al.
Publicado: (2011)

Suppression of PKCδ/NF-κB Signaling and Apoptosis Induction through Extrinsic/Intrinsic Pathways Are Associated with Magnolol-Inhibited Tumor Progression in Colorectal Cancer In Vitro and In Vivo
por: Su, Chun-Min, et al.
Publicado: (2020)

Magnolol Reduces Glutamate-Induced Neuronal Excitotoxicity and Protects against Permanent Focal Cerebral Ischemia Up to 4 Hours
por: Lee, Wei-Ting, et al.
Publicado: (2012)

Potential usefulness of (68)Ga-citrate PET/CT in detecting infected lower limb prostheses
por: Tseng, Jing-Ren, et al.
Publicado: (2019)

Magnolol inhibits venous remodeling in mice
por: Kuk, Hanna, et al.
Publicado: (2017)

Honokiol and Magnolol: Insights into Their Antidermatophytic Effects
por: Trifan, Adriana, et al.
Publicado: (2021)

Honokiol and Magnolol as Multifunctional Antioxidative Molecules for Dermatologic Disorders
por: Shen, Jui-Lung, et al.
Publicado: (2010)

Initial evaluation of (4S)-4-(3-[(18)F]fluoropropyl)-l-glutamate (FSPG) PET/CT imaging in patients with head and neck cancer, colorectal cancer, or non-Hodgkin lymphoma
por: Park, Sonya Y., et al.
Publicado: (2020)

Protein Kinase B Inactivation Is Associated with Magnolol-Enhanced Therapeutic Efficacy of Sorafenib in Hepatocellular Carcinoma In Vitro and In Vivo
por: Chen, Jiann-Hwa, et al.
Publicado: (2019)

Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update
por: Lin, Yiping, et al.
Publicado: (2021)

Synthesis, anti-aging and mechanism of magnolol derivatives
por: Pang, Xinxin, et al.
Publicado: (2023)

Pharmacodynamic Analysis of Magnetic Resonance Imaging-Monitored Focused Ultrasound-Induced Blood-Brain Barrier Opening for Drug Delivery to Brain Tumors
por: Chu, Po-Chun, et al.
Publicado: (2013)

Magnolol and Honokiol Inhibited the Function and Expression of BCRP with Mechanism Exploration
por: Yu, Chung-Ping, et al.
Publicado: (2021)

Plasma Aβ analysis using magnetically-labeled immunoassays and PET (18)F-florbetapir binding in non-demented patients with major depressive disorder
por: Wu, Kuan-Yi, et al.
Publicado: (2018)

Molecular Determinants of Magnolol Targeting Both RXRα and PPARγ
por: Zhang, Haitao, et al.
Publicado: (2011)

Author Correction: Plasma Aβ analysis using magnetically-labeled immunoassays and PET (18)F-florbetapir binding in non-demented patients with major depressive disorder
por: Wu, Kuan-Yi, et al.
Publicado: (2019)

The MPTP Story
por: Langston, J. William
Publicado: (2017)

Induction of Apoptosis, Inhibition of MCL-1, and VEGF-A Expression Are Associated with the Anti-Cancer Efficacy of Magnolol Combined with Regorafenib in Hepatocellular Carcinoma
por: Chen, Cheng-Hsien, et al.
Publicado: (2021)

Autophagy triggered by magnolol derivative negatively regulates angiogenesis
por: Kumar, S, et al.
Publicado: (2013)

Inhibitory effects of magnolol and honokiol on human calcitonin aggregation
por: Guo, Caiao, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bfn7mgpibvjqg2geo8snmhbisa